WestPark Capital analyst Ed Arce initiated coverage of Talphera (TLPH) with a Buy rating and $3 price target The firm says the company is brining the best continuous renal replacement therapy anticoagulant in the U.S. with data expected by the end of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLPH: